Alnylam Pharma (ALNY) Tops Q2 EPS by 91c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $247.51 -4.07%
EPS Growth %: -39.0%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -39.0%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of $0.32, $0.91 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $773.69 million versus the consensus estimate of $643.2 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Microsoft plans data center push to triple its computing power - Bloomberg
- Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance
- Morgan Stanley Reiterates Overweight Rating on Kingspan Group PLC (KSP:ID), Adds to Top Picks
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
